
# Stepwise Approach: 0-4 years

2020 EPR 3 Updates/GINA Hybrid



At every visit, check inhaler technique, medication adherence, and assess for environmental changes.



# **Stepwise Approach: 0-4 years**Additional Notes





### Alternative Reliever Therapy at Steps 3-5

Consider **SMART** (Single Maintenance and Reliever Therapy) in consultation with a specialist for ages 4+

ICS + Formoterol PRN

• 4 puffs at a time, max 8 puffs per day for maintenance + reliever



## At every visit:

- · check inhaler technique
- check medication adherence
- · assess any changes in environment



Consider consult with asthma specialist at Steps 2 and 3

Recommend consult with asthma specialist at Steps 4, 5, and 6



**Montelukast** has an **FDA Boxed Warning** due to risk of serious adverse neuropsychiatric side effects and is no longer recommended as an asthma controller medication.

#### **Abbreviations**

#### EPR 3

**Expert Panel Report 3** 

#### **GINA**

Global Initiative for Asthma

#### **PRN**

As Needed

#### ICS

Inhaled Corticosteroids

#### URI

Upper Respiratory Infection

#### **LABA**

Long-Acting Beta-Agonist

#### LAMA

Long-Acting Muscarinic Antagonist

#### ocs

Oral Corticosteroid